Acromegaly Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Ionis Pharmaceuticals, Chiasma Pharma, Antisense Therapeutics, Camurus

The Acromegaly market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acromegaly pipeline products will significantly revolutionize the Acromegaly market dynamics.  

Acromegaly Overview

Acromegaly is a hormonal disorder that results from the availability of excessive growth hormone (GH) in the body, which is produced by the pituitary gland (a small gland in the brain). In acromegaly, the pituitary produces an immoderate amount of GH, which is resulted from benign or noncancerous tumors on the pituitary. These benign tumors are called Adenomas.

The acromegaly symptoms vary from patient to patient. It can lead to unusual physical features, such as swollen hands and feet, deformities, and complications, with an impact also on muscle strength and bone health. 

Some of the key facts of the Acromegaly Market Report: 

• The Acromegaly market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
• The growth factors for the Acromegaly market include the robust clinical pipeline and effectiveness of both mono and combination therapies 
• The total number of prevalent cases of acromegaly in was found to be 5,00,022 cases in the 7MM 
• In the EU5, the highest prevalent cases were observed in Germany, followed by France and Italy, whereas the lowest prevalent cases were witnessed in Spain 
• Many clinical trials are going on to bring more potential therapy to the market, either in the form of a new molecule or a better formulation of existing Acromegaly therapies 
• Key Acromegaly Companies: Ionis Pharmaceuticals, Chiasma Pharma, Antisense Therapeutics, Camurus, Stringbridge Biopharma, Crinetics Pharmaceuticals, Midatech, and others 
• Key Acromegaly Therapies: IONIS-GHR-LR, Octreotide Capsules (Mycapssa), ATL1103 (Atesidorsen), CAM2029, Veldoreotide (formerly COR005, DG3173), CRN00808, MTD201, and others 
• The Acromegaly epidemiology based on gender analyzed that the majority of the cases of Acromegaly is originated with adenomas at the Pituitary gland and the rest are because of benign tumors at other sites

Get a Free sample for the Acromegaly Market Report 

Key benefits of the Acromegaly Market report:

1. Acromegaly market report covers a descriptive overview and comprehensive insight of the Acromegaly Epidemiology and Acromegaly market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Acromegaly market report provides insights on the current and emerging therapies.
3. Acromegaly market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Acromegaly market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Acromegaly market.

Discover more about therapies set to grab major Acromegaly market share @ Acromegaly market forecast

Acromegaly Epidemiology Segmentation:

The Acromegaly market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Acromegaly
• Prevalent Cases of Acromegaly by severity
• Gender-specific Prevalence of Acromegaly
• Diagnosed Cases of Episodic and Chronic Acromegaly 

Acromegaly Market  

The dynamics of the Acromegaly market are anticipated to change in the coming years owing to the expected launch of Acromegaly emerging therapies such as Octreotide capsules, Veldoreotide, CAM2029, and others during the forecasted period 2019-2032. 

Download the report to understand which factors are driving Acromegaly epidemiology trends @ Acromegaly Epidemiological Insights 

Acromegaly Market Drivers

• Rich Acromegaly emerging pipeline
• Rise in Acromegaly awareness
• More efficacious mono and combinational therapies

Acromegaly Therapies and Key Companies

• IONIS-GHR-LR: Ionis Pharmaceuticals
• Octreotide Capsules (Mycapssa): Chiasma Pharma
• ATL1103 (Atesidorsen): Antisense Therapeutics
• CAM2029: Camurus
• Veldoreotide (formerly COR005, DG3173): Stringbridge Biopharma
• CRN00808: Crinetics Pharmaceuticals
• MTD201: Midatech 

Scope of the Acromegaly Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acromegaly Companies:  Ionis Pharmaceuticals, Chiasma Pharma, Antisense Therapeutics, Camurus, Stringbridge Biopharma, Crinetics Pharmaceuticals, Midatech, and others
• Key Acromegaly Therapies:  IONIS-GHR-LR, Octreotide Capsules (Mycapssa), ATL1103 (Atesidorsen), CAM2029, Veldoreotide (formerly COR005, DG3173), CRN00808, MTD201, and others
• Acromegaly Therapeutic Assessment:  Acromegaly current marketed and Acromegaly emerging therapies
• Acromegaly Market Dynamics:  Acromegaly market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Acromegaly  Market Access and Reimbursement 

Acromegaly Market Barriers

• High-economic burden
• Delay in Acromegaly diagnosis
• No cure available

Table of Contents 

1. Acromegaly Market Report Introduction

2. Executive Summary for Acromegaly

3. SWOT analysis of Acromegaly

4. Acromegaly Patient Share (%) Overview at a Glance

5. Acromegaly Market Overview at a Glance

6. Acromegaly Disease Background and Overview

7. Acromegaly Epidemiology and Patient Population

8. Country-Specific Patient Population of Acromegaly 

9. Acromegaly Current Treatment and Medical Practices

10. Acromegaly Unmet Needs

11. Acromegaly Emerging Therapies

12. Acromegaly Market Outlook

13. Country-Wise Acromegaly Market Analysis (2019–2032)

14. Acromegaly Market Access and Reimbursement of Therapies

15. Acromegaly Market drivers

16. Acromegaly Market barriers

17.  Acromegaly Appendix

18. Acromegaly Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Acromegaly treatment, visit @ Acromegaly Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/